Biohaven Ltd. (BHVN) stock
BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
$12.90−0.34 (-2.57%)
Close on Nov 18, 2026Market cap $1.95BP/E –Yield –
Biohaven operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Biohaven's operating income for the twelve months ending Sep 30, 2026 was -$524.48M. For fiscal 2025 it was -$745.38M. The highest annual figure on record is -$114.51M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$745.38M | – |
| FY2024 | Dec 31, 2024 | -$885.11M | – |
| FY2023 | Dec 31, 2023 | -$436.05M | – |
| FY2022 | Dec 31, 2022 | -$567.93M | – |
| FY2021 | Dec 31, 2021 | -$218.90M | – |
| FY2020 | Dec 31, 2020 | -$114.51M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$126.42M | – |
| Q2 FY2026 | Jun 30, 2026 | -$124.90M | – |
| Q1 FY2026 | Mar 31, 2026 | -$130.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$142.73M | – |
| Q3 FY2025 | Sep 30, 2025 | -$169.38M | – |
| Q2 FY2025 | Jun 30, 2025 | -$211.70M | – |
| Q1 FY2025 | Mar 31, 2025 | -$221.56M | – |
| Q4 FY2024 | Dec 31, 2024 | -$189.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$178.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$333.77M | – |
| Q1 FY2024 | Mar 31, 2024 | -$183.24M | – |
| Q4 FY2023 | Dec 31, 2023 | -$153.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$110.55M | – |
| Q2 FY2023 | Jun 30, 2023 | -$94.01M | – |
| Q1 FY2023 | Mar 31, 2023 | -$77.78M | – |
| Q4 FY2022 | Dec 31, 2022 | -$213.41M | – |
| Q3 FY2022 | Sep 30, 2022 | -$67.64M | – |
| Q2 FY2022 | Jun 30, 2022 | -$197.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$89.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$50.88M | – |
| Q3 FY2021 | Sep 30, 2021 | -$55.49M | – |
See a number that looks wrong?